Patents by Inventor Kevin Brindle

Kevin Brindle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSIS AND MONITORING OF BRAIN CANCER
    Publication number: 20240290489
    Abstract: The present invention provides a computer-implemented method for analysing a urine sample from a subject. The method comprises providing the value of one or more cell-free DNA fragment size metrics for said sample, and determining whether the sample has a high or low likelihood of being from a brain cancer patient by providing said values of said cell-free DNA fragment size metrics as input to a machine learning model. The machine learning model is trained to classify sample data into one of at least two classes, the at least two classes comprising a first class having a high likelihood of being from a brain cancer patient and a second class having a low likelihood of being from a brain cancer patient. Methods for diagnosing or screening for brain cancer, detecting recurrence or residual disease, providing a prognosis or selecting a treatment for brain cancer are also described.
    Type: Application
    Filed: July 8, 2022
    Publication date: August 29, 2024
    Applicants: Cambridge Enterprise Limited, Stichting Amsterdam UMC
    Inventors: Kevin Brindle, Richard Mair, Florent Moulière, Nitzan Rosenfeld, Christopher G. Smith
  • Hyperpolarized lactate contrast agent for determination of LDH activity
    Patent number: 9408925
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarized [13C, 2H] lactate.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 9, 2016
    Assignee: General Electric Company
    Inventors: Kevin Brindle, Mikko Kettunen, Brett Kennedy
  • HYPERPOLARIZED LACTATE CONTRAST AGENT FOR DETERMINATION OF LDH ACTIVITY
    Publication number: 20160184462
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H] lactate.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Inventors: Kevin Brindle, Mikko Kettunen, Brett Kennedy
  • Hyperpolarized lactate contrast agent for determination of LDH activity
    Patent number: 9259490
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarized [13C, 2H]lactate.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: February 16, 2016
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Kevin Brindle, Mikko Iivari Kettunen, Brett W.C. Kennedy
  • Agents for detecting and imaging cell death
    Patent number: 8685371
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumors following cancer treatment.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 1, 2014
    Assignee: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam
  • HYPERPOLARIZED LACTATE CONTRAST AGENT FOR DETERMINATION OF LDH ACTIVITY
    Publication number: 20130052141
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H]lactate.
    Type: Application
    Filed: May 2, 2011
    Publication date: February 28, 2013
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Kevin Brindle, Mikko Iivari Kettunen, Brett W.C. Kennedy
  • AGENTS FOR DETECTING AND IMAGING CELL DEATH
    Publication number: 20110038798
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumours following cancer treatment.
    Type: Application
    Filed: April 29, 2009
    Publication date: February 17, 2011
    Applicant: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam